In the last update of the World Health Organization (WHO) classification, the marginal zone
B-cell lymphomas (MZLs) comprise extranodal MZL (EMZL) of mucosa-associated lymphoid …

Abstract The activator protein-1 (AP-1) is a dimeric transcription factor composed of proteins
belonging to the Jun (c-Jun, JunB and JunD), Fos (c-Fos, FosB, Fra1 and Fra2) and …

Splenic marginal zone lymphoma (SMZL) is a low-grade B-cell non-Hodgkin's lymphoma
characterized by massive splenomegaly, moderate lymphocytosis with or without villous …

Background Histologic transformation (HT) is a poorly understood event in patients with
marginal zone lymphoma (MZL). The aim of this study was to analyze incidence and risk …

We describe 36 patients with splenic marginal zone lymphoma (SMZL) with transformation
(SMZL‐T), including 15 from a series of 84 patients with SMZL diagnosed at the Hospital …

Purpose The detection rate and the metabolic behavior of 18F-FDG-PET/CT in splenic
marginal zone lymphoma (SMZL) are not yet clear. Our aim was to investigate the metabolic …

Background Marginal zone lymphoma (MZL) is a non-Hodgkin lymphoma that occurs as
extra nodal, nodal, or splenic. While MZL is generally considered an indolent disease, a …

NF-κB and Notch signaling can be simultaneously activated in a variety of B-cell
lymphomas. Patients with B-cell lymphoma occasionally develop clonally related myeloid …

Despite diagnostic and therapeutic advances, the majority of patients with splenic marginal
zone lymphoma (SMZL) are still treated with splenectomy. We analyzed survival outcomes …

Marginal zone lymphomas (MZL) represent around 8% of all non-Hodgkin lymphomas.
During the last decades a number of studies have addressed the mechanisms underlying …